Selecta Biosciences’ (SELB) Buy Rating Reaffirmed at Canaccord Genuity

Selecta Biosciences (NASDAQ:SELB)‘s stock had its “buy” rating restated by equities researchers at Canaccord Genuity in a report issued on Thursday. They presently have a $30.00 target price on the stock. Canaccord Genuity’s target price suggests a potential upside of 221.54% from the company’s previous close.

The analysts wrote, “We expect the combination dosing to provide rapid, sustained SUA lowering similarly to what has been seen for the combination SEL-212 + SVP dosing in the ongoing Phase 2 trial.””

SELB has been the subject of several other research reports. Zacks Investment Research upgraded shares of Selecta Biosciences from a “hold” rating to a “buy” rating and set a $10.00 price target for the company in a report on Saturday, November 11th. ValuEngine lowered shares of Selecta Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, September 26th. Finally, UBS Group lowered shares of Selecta Biosciences from a “buy” rating to a “neutral” rating in a research note on Thursday, November 9th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. Selecta Biosciences has a consensus rating of “Hold” and an average price target of $23.50.

Selecta Biosciences (SELB) traded up $0.39 during trading hours on Thursday, hitting $9.33. 334,637 shares of the stock traded hands, compared to its average volume of 207,996. Selecta Biosciences has a twelve month low of $8.40 and a twelve month high of $24.02. The company has a debt-to-equity ratio of 0.32, a quick ratio of 9.48 and a current ratio of 9.48. The company has a market cap of $205.95 and a price-to-earnings ratio of -3.01.

Selecta Biosciences (NASDAQ:SELB) last posted its quarterly earnings results on Tuesday, November 7th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.22. Selecta Biosciences had a negative net margin of 1,918.59% and a negative return on equity of 100.06%. sell-side analysts expect that Selecta Biosciences will post -2.25 EPS for the current fiscal year.

In other news, insider Werner Cautreels acquired 20,000 shares of Selecta Biosciences stock in a transaction that occurred on Monday, November 13th. The stock was purchased at an average price of $9.31 per share, for a total transaction of $186,200.00. Following the purchase, the insider now directly owns 321,203 shares in the company, valued at approximately $2,990,399.93. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Timothy C. Barabe acquired 5,000 shares of Selecta Biosciences stock in a transaction that occurred on Friday, November 10th. The shares were purchased at an average price of $9.37 per share, with a total value of $46,850.00. Following the purchase, the director now owns 4,992 shares in the company, valued at $46,775.04. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 90,098 shares of company stock valued at $843,933. 41.90% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of SELB. Schwab Charles Investment Management Inc. bought a new position in shares of Selecta Biosciences during the 2nd quarter worth approximately $392,000. Rhumbline Advisers purchased a new stake in Selecta Biosciences during the 2nd quarter worth approximately $239,000. Bank of New York Mellon Corp grew its position in Selecta Biosciences by 119.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 32,400 shares of the company’s stock worth $644,000 after purchasing an additional 17,664 shares during the last quarter. JPMorgan Chase & Co. grew its position in Selecta Biosciences by 46.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 358,846 shares of the company’s stock worth $7,126,000 after purchasing an additional 114,477 shares during the last quarter. Finally, Teachers Advisors LLC grew its position in Selecta Biosciences by 294.2% during the 2nd quarter. Teachers Advisors LLC now owns 21,292 shares of the company’s stock worth $423,000 after purchasing an additional 15,890 shares during the last quarter. Hedge funds and other institutional investors own 54.44% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Selecta Biosciences’ (SELB) Buy Rating Reaffirmed at Canaccord Genuity” was published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://transcriptdaily.com/2018/01/19/selecta-biosciences-selb-buy-rating-reaffirmed-at-canaccord-genuity.html.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply